...
首页> 外文期刊>Pediatric surgery international >Conservative treatment of infantile hypertrophic pyloric stenosis with intravenous atropine sulfate does not replace pyloromyotomy.
【24h】

Conservative treatment of infantile hypertrophic pyloric stenosis with intravenous atropine sulfate does not replace pyloromyotomy.

机译:静脉注射硫酸阿托品对小儿肥厚性幽门狭窄的保守治疗不能代替幽门切开术。

获取原文
获取原文并翻译 | 示例
           

摘要

Pyloromyotomy as described by Weber and Ramstedt has been the standard therapy for infantile hypertrophic pyloric stenosis since the 1960's and conservative therapy has been abandoned. The objective of this study was to test the effectiveness of systemic atropine applied intravenously for 7 days as a conservative therapeutic strategy and as an alternative to primary operation. Forty-two consecutive term infants with infantile hypertrophic pyloric stenosis were enrolled in the study over a period of 5 years. After confirmation of the diagnosis they all received intravenous atropine at a dose of 0.04 mg/(kg day) and increased by 0.01 mg/(kg day) up to 0.12 mg/(kg day), given as 6-8 single doses per/day. Nine pairs of parents requested that their child should be operated before completing the 7 days of medical therapy. Surgery was necessary in 8 of the remaining 33 infants (24,.2%) who did not improve after 7 days of conservative treatment. Successful treatment with i.v. atropine sulfate was achieved onlyin 25/33 term infants at an average maximal dose of 0.11 mg/(kg day), without any major side effects. Intravenous atropine sulfate has been considered as a potential alternative therapeutic strategy in the treatment of infantile hypertrophic pyloric stenosis. Clinical improvement however was often not seen before the 6th or 7th day of intravenous treatment. A success rate for the conservative approach of only 75% at day 7 in our study does not favour atropine therapy, in view of success rates above 95% with surgical repair.
机译:自1960年代以来,Weber和Ramstedt所描述的幽门切开术一直是婴儿肥厚性幽门狭窄的标准治疗方法,而保守治疗已被放弃。这项研究的目的是测试静脉注射全身性阿托品7天作为保守治疗策略和替代主要手术方法的有效性。在5年的时间内,该研究共纳入42例患有婴儿肥厚性幽门狭窄的足月婴儿。确诊后,他们全部接受0.04 mg /(kg·天)剂量的静脉内阿托品治疗,并以0.01 / mg /(kg·天)的剂量增加至0.12 mg /(kg·天),以6-8单次剂量//天。 9对父母要求在完成7天药物治疗之前应该对其孩子进行手术。其余33例婴儿中有8例(24..2%)需要手术,但在保守治疗7天后仍无好转。 i.v.的成功治疗仅在25/33足月婴儿中获得硫酸阿托品,平均最大剂量为0.11 mg /(kg·天),无任何重大副作用。静脉注射硫酸阿托品被认为是治疗婴儿肥厚性幽门狭窄的一种潜在的替代治疗策略。然而,在静脉内治疗的第6天或第7天之前通常看不到临床改善。鉴于手术修复的成功率超过95%,在我们的研究中,第7天保守治疗的成功率仅75%不支持阿托品治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号